Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alhopuro, P.
Right arrow Articles by Aaltonen, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alhopuro, P.
Right arrow Articles by Aaltonen, L. A.
[Cancer Research 64, 7245-7247, October 15, 2004]
© 2004 American Association for Cancer Research


Advances in Brief

NOD2 3020insC Alone Is Not Sufficient for Colorectal Cancer Predisposition

Pia Alhopuro1, Taru Ahvenainen1, Jukka-Pekka Mecklin2, Matti Juhola3, Heikki J. Järvinen4, Auli Karhu1 and Lauri A. Aaltonen1

1 Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland; Departments of 2 Surgery and 3 Pathology, Jyväskylä Central Hospital, Jyväskylä, Finland; and 4 The Second Department of Surgery, Helsinki University Hospital, Helsinki, Finland

Mutations in NOD2 have been shown to associate with increased susceptibility to Crohn’s disease. A recent Polish study linked the truncating NOD2 3020insC variant with an increased risk of colorectal cancer (CRC) at an older age (>50 years) of disease onset, with an odds ratio of 2.23. We studied the possible contribution of the 3020insC variant to CRC risk in a series of 1,042 Finnish population-based patients from which 926 samples were successfully analyzed and in 348 anonymous cancer-free controls. The frequency of the 3020insC mutation was 3.7% in both CRC patients (34 of 926, including 1 homozygote) and cancer-free controls (13 of 348; odds ratio, 0.98; confidence interval, 0.51–1.88). Contrary to the Polish study, there was no significant difference in the mutation rates between CRC patients > 50 years of age (25 of 576; 4.3%) and controls in the present series. We studied respective tumor tissue DNAs of all patients displaying heterozygous 3020insC changes for loss of heterozygosity. Loss of heterozygosity at NOD2 was observed in only 1 of the 33 CRC samples. Our results suggest that NOD2 3020insC alone does not contribute to CRC risk. If this variant predisposes to CRC, additional factors not present in the Finnish population need to be involved.




This article has been cited by other articles:


Home page
Cancer Res.Home page
R. L. Roberts, R. B. Gearry, M. D.E. Allington, H. R. Morrin, B. A. Robinson, and F. A. Frizelle
Caspase recruitment domain-containing protein 15 mutations in patients with colorectal cancer.
Cancer Res., March 1, 2006; 66(5): 2532 - 2535.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.